Antiopioid activity of the cardioexcitatory peptide in central modulation of cardiovascular functions.
Intracerebroventricular (i.c.v.) injection of [D-Ala2,Leu5]enkephalin produced depressor and bradycardiac responses which were prevented by naloxone or FMRF-NH2 pretreatment. Intrathecal injection of FMRF-NH2 to rats in hemorrhagic shock resulted in a slight but significant increase in blood pressure, and prevented the further decrease in heart rate which was observed in the control group. It is concluded that FMRF-NH2 may act as an antiopioid substance in central modulation of cardiovascular functions.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D004723:Endorphins / Q000037:antagonists & inhibitors*; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D019835:FMRFamide; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D051381:Rats; D012771:Shock, Hemorrhagic / Q000503:physiopathology
D004723:Endorphins; D009419:Nerve Tissue Proteins; D009270:Naloxone; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D019835:FMRFamide; C030279:enkephalinamide-Leu, Ala(2)-